Drug Profile
IRAK4 kinase inhibitor - Bristol-Myers Squibb
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Pyridines; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Immunological-disorders in USA